The abstract is read at the publisher; the summary is JClub's.
Higher RA inflammatory arthritis genetic risk score is linked to greater odds of TNFi-to-abatacept and multi–b/tsDMARD cycling versus TNFi persistence in 2,454 MVP and 461 MGB patients.
- Why it matters: Selecting biologic and targeted synthetic DMARD regimens in rheumatoid arthritis is difficult, and genetic factors that track with real-world treatment trajectories are not well defined.
- What they did: Using electronic health records linked to genotyping from the Million Veteran Program and Mass General Brigham Biobank, the study used mixture Markov modeling to define b/tsDMARD patterns and logistic regression to test associations with inflammatory arthritis GRS.
- The result: In meta-analysis, RA GRS predicted higher odds for TNFi-to-abatacept (OR 1.129, 95%CI 1.008–1.264) and multi–b/tsDMARD cycling (OR 1.137, 95%CI 1.056–1.223) versus TNFi persisters, while spondyloarthritis GRS showed lower odds for those patterns and higher odds for TNFi persistence.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.